DDR2 and arthritic joint disease: Although imatinib is not a selective inhibitor for DDRs, it is possible that inhibition of DDR2 by imatinib contributes to the suppressive effect in arthritis development, and DDR2-selective inhibition may be a potential novel therapeutic strategy for RA therapy in the future.